Immunic Inc. (NASDAQ: IMUX) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on IMUX since May 13, 2026, most recently "Immunic (NASDAQ:IMUX) Q2 2026 EPS of $(0.80) Beats Estimate; Elena Ridloff Joins Board" on Tuesday, August 11, 2026. Coverage to date spans Earnings Report, tracking IMUX's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Immunic posted Q2 EPS of $(0.80), beating the $(1.10) consensus by 27.27%, while appointing a veteran biopharma CFO to its board ahead of a Phase 3 MS readout.
Immunic posted a Q1 2026 net loss of $32.6M as it continues funding its Phase 3 ENSURE trials. A new CMO appointment and strong analyst backing underpin the outlook.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.